NCT03385486招募中1 期
A Phase 1 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 72
- 试验地点
- 4
- 主要终点
- Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
研究概览
简要总结
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors.
The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity.
The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following inclusion criteria to be eligible for participation in the study:
- •Histopathologically confirmed diagnosis of advanced, unresectable or metastatic malignant melanoma
- •Male or female patients age 18 or older
- •Previously treated with checkpoint inhibitor therapy either alone or in combination with either stable disease or progressive disease per RECIST version 1.1 (there is no minimum treatment duration for patients who have progressive disease while on checkpoint inhibitor therapy)
- •Measurable or evaluable disease by RECIST version 1.1
- •Capable of understanding and complying with protocol requirements
- •A life expectancy of greater than 24 weeks at Screening
- •ECOG Performance Status of 0 to 2
- •Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures
- •Adequate bone marrow, liver, and renal function as defined below:
- •hemoglobin ≥8.0 g/dL (transfusions allowed)
- •absolute neutrophil count ≥1500/µL
- •platelet count ≥100,000/µL (transfusions allowed)
- •alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of normal (ULN), or ≤5 times ULN for patients with known hepatic metastases
- •total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are present; patients with a known history of Gilbert's syndrome (≤3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
- •estimated glomerular filtration rate ≥50 mL/min/1.73 m^2 (using Cockcroft Gault formula)
排除标准
- •Patients who meet any of the following criteria will not be eligible for participation in the study:
- •Pregnant or breast feeding
- •Developed immune-related toxicity while on prior checkpoint inhibitor therapy that has not yet returned to Grade 1 or better
- •Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted
- •Active, symptomatic central nervous system (CNS) metastases. Patients with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening
- •Any concurrent uncontrolled illness, including mental illness or substance abuse which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial
- •Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident
- •Women of childbearing potential who are unable or unwilling to use an acceptable method of contraception
- •Known infection with human immunodeficiency virus (HIV) that is not well controlled on anti-retroviral therapy as defined by HIV RNA more than 400 copies/mL or severely symptomatic
- •Presence of Hepatitis B and/or Hepatitis C active infection
- •Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher
结局指标
主要结局
Incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
时间窗: 26 months
Adverse events from subject reporting
次要结局
- Tumor responses as defined by irRECIST(26 months)
- Presence and/or concentration of anti TBX-3400 antibodies(26 months)
- Assessment of concentrations of certain chemokines, such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400(26 months)
- Tumor responses as defined by RECIST version 1.1(26 months)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
1 期
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard TherapiesTumor, SolidRefractory CancerCancerNCT04640246Taiga Biotechnologies, Inc.60
已完成
1 期
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory MedulloblastomaRelapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)NCT02748135Oncurious NV18
招募中
1 期
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast CancerBreast CancerNCT06515470Biotheryx, Inc.82
Unknown
1 期
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 TabletsAdvanced Solid Tumor or Hematologic TumorNCT04481607Chia Tai Tianqing Pharmaceutical Group Co., Ltd.96
已完成
1 期
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsPeripheral T-cell LymphomaNCT02809573Chipscreen Biosciences, Ltd.30